Engineered bacteriophage lysins as novel anti-infectives

Frontiers in Microbiology

Volumn 5, Issue OCT, 2014, Pages

  Yang, Hang ^a   Yu, Junping ^a   Wei, Hongping ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Artilysin; Bacteriophage; Chimeolysin; Enzybiotics; Lysin; Lysin engineering

Indexed keywords

ARTILYSIN; CHIMEOLYSIN; LYSIN; PEPTIDOGLYCAN; UNCLASSIFIED DRUG; VIRAL PROTEIN;

BACTERIOPHAGE; CYTOLYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG SPECIFICITY; ENZYME ACTIVE SITE; HYDROLYSIS; MEMBRANE BINDING; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN STRUCTURE; SHORT SURVEY;

EID: 84987849551     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00542     Document Type: Short Survey

References (74)

1. Abedon, S. T. (2011). Lysis from without. Bacteriophage 1, 46-49. doi: 10.4161/bact.1.1.13980
2. Becker, S. C., Foster-Frey, J., Stodola, A. J., Anacker, D., and Donovan, D. M. (2009). Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 443, 32-41. doi: 10.1016/j.gene.2009.04.023
3. Briers, Y., Cornelissen, A., Aertsen, A., Hertveldt, K., Michiels, C. W., Volckaert, G., et al. (2008). Analysis of outer membrane permeability of Pseudomonas aeruginosa and bactericidal activity of endolysins KZ144 and EL188 under high hydrostatic pressure. FEMS Microbiol. Lett. 280, 113-119. doi: 10.1111/j.1574-6968.2007.01051.x
4. Briers, Y., Volckaert, G., Cornelissen, A., Lagaert, S., Michiels, C. W., Hertveldt, K., et al. (2007). Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages phiKZ and EL. Mol. Microbiol. 65, 1334-1344. doi: 10.1111/j.1365-2958.2007.05870.x
5. Briers, Y., Walmagh, M., Grymonprez, B., Biebl, M., Pirnay, J. P., Defraine, V., et al. (2014a). Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58, 3774-3784. doi: 10.1128/AAC.02668-14
6. Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., et al. (2014b). Engineered endolysin-based "artilysins" to combat multidrug-resistant gram-negative pathogens. MBio 5, e01379-14. doi: 10.1128/mBio.01379-14
7. Callewaert, L., Walmagh, M., Michiels, C. W., and Lavigne, R. (2011). Food applications of bacterial cell wall hydrolases. Curr. Opin. Biotechnol. 22, 164-171. doi: 10.1016/j.copbio.2010.10.012
8. Cheng, Q., Nelson, D., Zhu, S., and Fischetti, V. A. (2005). Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49, 111-117. doi: 10.1128/AAC.49.1.111-117.2005
9. Coello, R., Jimenez, J., Garcia, M., Arroyo, P., Minguez, D., Fernandez, C., et al. (1994). Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur. J. Clin. Microbiol. Infect. Dis. 13, 74-81. doi: 10.1007/BF02026130
10. Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., and Fischetti, V. A. (2010). Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54, 1603-1612. doi: 10.1128/AAC.01625-09
11. Dawson, R. M., and Liu, C. Q. (2009). Cathelicidin peptide SMAP-29: comprehensive review of its properties and potential as a novel class of antibiotics. Drug Develop. Res. 70, 481-498. doi: 10.1002/ddr.20329
12. De Lencastre, H., Kristinsson, K. G., Brito-Avo, A., Sanches, I. S., Sa-Leao, R., Saldanha, J., et al. (1999). Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb. Drug Resist. 5, 19-29. doi: 10.1089/mdr.1999.5.19
13. Diaz, E., Lopez, R., and Garcia, J. L. (1990). Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes. Proc. Natl. Acad. Sci. U.S.A. 87, 8125-8129. doi: 10.1073/pnas.87.20.8125
14. Dong, Q., Wang, J., Yang, H., Yu, J., Zhang, Y., Huang, Y., et al. (2014). Construction of a chimeric lysin Ply187N-V12C with extended lytic activity against staphylococci and streptococci. Microb. Biotechnol. doi: 10.1111/1751-7915.12166. [Epub ahead of print].
15. Donovan, D. M., Dong, S., Garrett, W., Rousseau, G. M., Moineau, S., and Pritchard, D. G. (2006a). Peptidoglycan hydrolase fusions maintain their parental specificities. Appl. Environ. Microbiol. 72, 2988-2996. doi: 10.1128/AEM.72.4.2988-2996.2006
16. Donovan, D. M., and Foster-Frey, J. (2008). LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5 domain for antimicrobial lysis of streptococci. FEMS Microbiol. Lett. 287, 22-33. doi: 10.1111/j.1574-6968.2008.01287.x
17. Donovan, D. M., Lardeo, M., and Foster-Frey, J. (2006b). Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol. Lett. 265, 133-139. doi: 10.1111/j.1574-6968.2006.00483.x
18. Entenza, J. M., Loeffler, J. M., Grandgirard, D., Fischetti, V. A., and Moreillon, P. (2005). Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob. Agents Chemother. 49, 4789-4792. doi: 10.1128/AAC.49.11.4789-4792.2005
19. Eugster, M. R., Haug, M. C., Huwiler, S. G., and Loessner, M. J. (2011). The cell wall binding domain of Listeria bacteriophage endolysin PlyP35 recognizes terminal GlcNAc residues in cell wall teichoic acid. Mol. Microbiol. 81, 1419-1432. doi: 10.1111/j.1365-2958.2011.07774.x
20. Eugster, M. R., and Loessner, M. J. (2012). Wall teichoic acids restrict access of bacteriophage endolysin Ply118, Ply511, and PlyP40 cell wall binding domains to the Listeria monocytogenes peptidoglycan. J. Bacteriol. 194, 6498-6506. doi: 10.1128/JB.00808-12
21. Fenton, M., Casey, P. G., Hill, C., Gahan, C. G., Ross, R. P., McAuliffe, O., et al. (2010a). The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng. Bugs 1, 404-407. doi: 10.4161/bbug.1.6.13422
22. Fenton, M., Ross, P., McAuliffe, O., O'Mahony, J., and Coffey, A. (2010b). Recombinant bacteriophage lysins as antibacterials. Bioeng. Bugs 1, 9-16. doi: 10.4161/bbug.1.1.9818
23. Fernandes, S., Proenca, D., Cantante, C., Silva, F. A., Leandro, C., Lourenco, S., et al. (2012). Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb. Drug Resist. 18, 333-343. doi: 10.1089/mdr.2012.0025
24. Fischetti, V. A. (2003). Novel method to control pathogenic bacteria on human mucous membranes. Ann. N.Y. Acad. Sci. 987, 207-214. doi: 10.1111/j.1749-6632.2003.tb06050.x
25. Fischetti, V. A. (2005). Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13, 491-496. doi: 10.1016/j.tim.2005.08.007
26. Fischetti, V. A. (2006). Using phage lytic enzymes to control pathogenic bacteria. BMC Oral Health 6(Suppl. 1):S16. doi: 10.1186/1472-6831-6-S1-S16
27. Fischetti, V. A. (2008). Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 11, 393-400. doi: 10.1016/j.mib.2008.09.012
28. Fischetti, V. A. (2010). Bacteriophage endolysins: a novel anti-infective to control gram-positive pathogens. Int. J. Med. Microbiol. 300, 357-362. doi: 10.1016/j.ijmm.2010.04.002
29. Fischetti, V. A., Nelson, D., and Schuch, R. (2006). Reinventing phage therapy: are the parts greater than the sum? Nat. Biotechnol. 24, 1508-1511. doi: 10.1038/nbt1206-1508
30. Garcia, E., Garcia, J. L., Garcia, P., Arraras, A., Sanchez-Puelles, J. M., and Lopez, R. (1988). Molecular evolution of lytic enzymes of Streptococcus pneumoniae and its bacteriophages. Proc. Natl. Acad. Sci. U.S.A. 85, 914-918. doi: 10.1073/pnas.85.3.914
31. George, S. E., Chikkamadaiah, R., Durgaiah, M., Joshi, A. A., Thankappan, U. P., Madhusudhana, S. N., et al. (2012). Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128. BMC Res. Notes 5:280. doi: 10.1186/1756-0500-5-280
32. Gilmer, D. B., Schmitz, J. E., Euler, C. W., and Fischetti, V. A. (2013). Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57, 2743-2750. doi: 10.1128/AAC.02526-12
33. Grandgirard, D., Loeffler, J. M., Fischetti, V. A., and Leib, S. L. (2008). Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J. Infect. Dis. 197, 1519-1522. doi: 10.1086/587942
34. Hermoso, J. A., Monterroso, B., Albert, A., Galan, B., Ahrazem, O., Garcia, P., et al. (2003). Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. Structure 11, 1239-1249. doi: 10.1016/j.str.2003.09.005
35. Horgan, M., O'Flynn, G., Garry, J., Cooney, J., Coffey, A., Fitzgerald, G. F., et al. (2009). Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl. Environ. Microbiol. 75, 872-874. doi: 10.1128/AEM.01831-08
36. Idelevich, E. A., Von Eiff, C., Friedrich, A. W., Iannelli, D., Xia, G., Peters, G., et al. (2011). In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob. Agents Chemother. 55, 4416-4419. doi: 10.1128/AAC.00217-11
37. Junjappa, R. P., Desai, S. N., Roy, P., Narasimhaswamy, N., Raj, J. R., Durgaiah, M., et al. (2013). Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma: potential applications. Vet. Res. Commun. 37, 217-228. doi: 10.1007/s11259-013-9565-y
38. Kiser, K. B., Cantey-Kiser, J. M., and Lee, J. C. (1999). Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect. Immun. 67, 5001-5006.
39. Knoll, B. M., and Mylonakis, E. (2014). Antibacterial bioagents based on principles of bacteriophage biology: an overview. Clin. Infect. Dis. 58, 528-534. doi: 10.1093/cid/cit771
40. Loeffler, J. M., Nelson, D., and Fischetti, V. A. (2001). Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294, 2170-2172. doi: 10.1126/science.1066869
41. Loessner, M. J. (2005). Bacteriophage endolysins-current state of research and applications. Curr. Opin. Microbiol. 8, 480-487. doi: 10.1016/j.mib.2005.06.002
42. Loessner, M. J., Gaeng, S., and Scherer, S. (1999). Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187. J. Bacteriol. 181, 4452-4460.
43. Loessner, M. J., Kramer, K., Ebel, F., and Scherer, S. (2002). C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol. Microbiol. 44, 335-349. doi: 10.1046/j.1365-2958.2002.02889.x
44. Loessner, M. J., Schneider, A., and Scherer, S. (1995). A new procedure for efficient recovery of DNA, RNA, and proteins from Listeria cells by rapid lysis with a recombinant bacteriophage endolysin. Appl. Environ. Microbiol. 61, 1150-1152.
45. Lukacik, P., Barnard, T. J., Keller, P. W., Chaturvedi, K. S., Seddiki, N., Fairman, J. W., et al. (2012). Structural engineering of a phage lysin that targets gram-negative pathogens. Proc. Natl. Acad. Sci. U.S.A. 109, 9857-9862. doi: 10.1073/pnas.1203472109
46. Maher, S., and McClean, S. (2006). Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem. Pharmacol. 71, 1289-1298. doi: 10.1016/j.bcp.2006.01.012
47. Manoharadas, S., Witte, A., and Blasi, U. (2009). Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol. 139, 118-123. doi: 10.1016/j.jbiotec.2008.09.003
48. Mao, J., Schmelcher, M., Harty, W. J., Foster-Frey, J., and Donovan, D. M. (2013). Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol. Lett. 1, 30-36. doi: 10.1111/1574-6968.12104
49. McGowan, S., Buckle, A. M., Mitchell, M. S., Hoopes, J. T., Gallagher, D. T., Heselpoth, R. D., et al. (2012). X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proc. Natl. Acad. Sci. U.S.A. 109, 12752-12757. doi: 10.1073/pnas.1208424109
50. Navarre, W. W., Ton-That, H., Faull, K. F., and Schneewind, O. (1999). Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl-glycine endopeptidase activity. J. Biol. Chem. 274, 15847-15856. doi: 10.1074/jbc.274.22.15847
51. Nelson, D., Schuch, R., Chahales, P., Zhu, S., and Fischetti, V. A. (2006). PlyC: a multimeric bacteriophage lysin. Proc. Natl. Acad. Sci. U.S.A. 103, 10765-10770. doi: 10.1073/pnas.0604521103
52. Obeso, J. M., Martinez, B., Rodriguez, A., and Garcia, P. (2008). Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. Int. J. Food Microbiol. 128, 212-218. doi: 10.1016/j.ijfoodmicro.2008.08.010
53. Oliveira, H., Azeredo, J., Lavigne, R., and Kluskens, L. D. (2012). Bacteriophage endolysins as a response to emerging foodborne pathogens. Trends Food Sci. Technol. 28, 103-115. doi: 10.1016/j.tifs.2012.06.016
54. Pastagia, M., Euler, C., Chahales, P., Fuentes-Duculan, J., Krueger, J. G., and Fischetti, V. A. (2011). A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob. Agents Chemother. 55, 738-744. doi: 10.1128/AAC.00890-10
55. Pastagia, M., Schuch, R., Fischetti, V. A., and Huang, D. B. (2013). Lysins: the arrival of pathogen-directed anti-infectives. J. Med. Microbiol. 62, 1506-1516. doi: 10.1099/jmm.0.061028-0
56. Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., et al. (2007). Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis. 196, 1237-1247. doi: 10.1086/521305
57. Rigden, D. J., Jedrzejas, M. J., and Galperin, M. Y. (2003). Amidase domains from bacterial and phage autolysins define a family of gamma-D, L-glutamate-specific amidohydrolases. Trends Biochem. Sci. 28, 230-234. doi: 10.1016/S0968-0004(03)00062-8
58. Sass, P., and Bierbaum, G. (2007). Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl. Environ. Microbiol. 73, 347-352. doi: 10.1128/AEM.01616-06
59. Schmelcher, M., Powell, A. M., Becker, S. C., Camp, M. J., and Donovan, D. M. (2012). Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78, 2297-2305. doi: 10.1128/AEM.07050-11
60. Schmelcher, M., Shabarova, T., Eugster, M. R., Eichenseher, F., Tchang, V. S., Banz, M., et al. (2010). Rapid multiplex detection and differentiation of Listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl. Environ. Microbiol. 76, 5745-5756. doi: 10.1128/AEM.00801-10
61. Schmelcher, M., Tchang, V. S., and Loessner, M. J. (2011). Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb. Biotechnol. 4, 651-662. doi: 10.1111/j.1751-7915.2011.00263.x
62. Schuch, R., Lee, H. M., Schneider, B. C., Sauve, K. L., Law, C., Khan, B. K., et al. (2014). Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J. Infect. Dis. 209, 1469-1478. doi: 10.1093/infdis/jit637
63. Schuch, R., Nelson, D., and Fischetti, V. A. (2002). A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418, 884-889. doi: 10.1038/nature01026
64. Sheehan, M. M., Garcia, J. L., Lopez, R., and Garcia, P. (1997). The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin. Mol. Microbiol. 25, 717-725. doi: 10.1046/j.1365-2958.1997.5101880.x
65. Singh, P. K., Donovan, D. M., and Kumar, A. (2014). Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob. Agents Chemother. 58, 4621-4629 doi: 10.1128/AAC.00126-14
66. Skerlavaj, B., Benincasa, M., Risso, A., Zanetti, M., and Gennaro, R. (1999). SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett. 463, 58-62. doi: 10.1016/S0014-5793(99)01600-2
67. Villa, T. G., and Crespo, P. V. (2010). Enzybiotics: Antibiotic Enzymes as Drugs and Therapeutics. Hoboken, NJ: John Wiley & Sons.
68. Vipra, A. A., Desai, S. N., Roy, P., Patil, R., Raj, J. M., Narasimhaswamy, N., et al. (2012). Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol. 12:41. doi: 10.1186/1471-2180-12-41
69. Wang, I. N., Smith, D. L., and Young, R. (2000). Holins: the protein clocks of bacteriophage infections. Annu. Rev. Microbiol. 54, 799-825. doi: 10.1146/annurev.micro.54.1.799
70. Witzenrath, M., Schmeck, B., Doehn, J. M., Tschernig, T., Zahlten, J., Loeffler, J. M., et al. (2009). Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit. Care Med. 37, 642-649. doi: 10.1097/CCM.0b013e31819586a6
71. Yang, H., Wang, D. B., Dong, Q., Zhang, Z., Cui, Z., Deng, J., et al. (2012). Existence of separate domains in lysin PlyG for recognizing Bacillus anthracis spores and vegetative cells. Antimicrob. Agents Chemother. 56, 5031-5039. doi: 10.1128/AAC.00891-12
72. Yang, H., Zhang, Y., Yu, J., Huang, Y., Zhang, X. E., and Wei, H. (2014). Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo. Antimicrob. Agents Chemother. 58, 536-542. doi: 10.1128/AAC.01793-13
73. Young, R. (1992). Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 56, 430-481.
74. Young, R., and Wang, I. (2006). "Phage lysis". in The Bacteriophages, ed R. Calendar (Oxford: Oxford University Press), 104-126.